JNJ 75229414
Alternative Names: JNJ-75229414; JNJ-9414; KLK2 CAR-T CellsLatest Information Update: 25 Oct 2021
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 06 Oct 2021 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater) in USA (IV) (NCT05022849)
- 31 Aug 2021 Janssen Research & Development plans a phase I trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA in September 2021 (NCT05022849)
- 31 Aug 2021 Preclinical trials in Prostate cancer in USA (IV) before August 2021